Evofem Biosciences, Inc. (EVFM)
| Previous close | 0.9434 |
| Open | 0.9214 |
| Bid | 0.8495 x 1100 |
| Ask | 0.8498 x 1000 |
| Day's range | 0.8210 - 0.9256 |
| 52-week range | 0.2750 - 14.6100 |
| Volume | |
| Avg. volume | 34,721,267 |
| Market cap | 29.442M |
| Beta (5Y monthly) | -1.68 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -19.0060 |
| Earnings date | 04 Aug 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 16.25 |
- PR Newswire
Evofem Biosciences Announces Strong Second Quarter 2022 Financial Results and Affirms 2022 Guidance
Evofem Biosciences, Inc., (Nasdaq: EVFM) ("Evofem" or the "Company"), today reported financial results for the three- and six-month periods ended June 30, 2022 and affirmed full-year 2022 guidance.
- PR Newswire
Evofem Biosciences Strengthens Board of Directors
Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced the appointment of Jenny Yip, a Managing Partner at life sciences investment fund Adjuvant Capital, to its Board of Directors. The appointment of Ms. Yip as a director expands the Board from five to six independent directors.
- PR Newswire
Evofem Announces Completion of Last Subject Last Visit (LSLV) in Registrational Phase 3 "EVOGUARD" Trial Evaluating Phexxi® for the Prevention of Chlamydia and Gonorrhea in Women
Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced that the last subject has completed her last visit in EVOGUARD, the Company's registrational Phase 3 trial evaluating the efficacy and safety of Phexxi® (lactic acid, citric acid, potassium bitartrate) for the prevention of chlamydia and gonorrhea infection in women. There are no prescription pharmaceuticals approved to prevent these sexually transmitted infections (STIs).
